These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32438200)

  • 1. Cyclopentadienyl ruthenium(II) carbosilane metallodendrimers as a promising treatment against advanced prostate cancer.
    Sanz Del Olmo N; Bajo AM; Ionov M; García-Gallego S; Bryszewska M; Gómez R; Ortega P; de la Mata FJ
    Eur J Med Chem; 2020 Aug; 199():112414. PubMed ID: 32438200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterofunctional ruthenium(II) carbosilane dendrons, a new class of dendritic molecules to fight against prostate cancer.
    Sanz Del Olmo N; Maroto-Diaz M; Quintana S; Gómez R; Holota M; Ionov M; Bryszewska M; Carmena MJ; Ortega P; Javier de la Mata F
    Eur J Med Chem; 2020 Dec; 207():112695. PubMed ID: 32882608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruthenium dendrimers against acute promyelocytic leukemia: 
    Michlewska S; Ionov M; Maroto-Díaz M; Szwed A; Ihnatsyeu-Kachan A; Abashkin V; Dzmitruk V; Rogalska A; Denel M; Gapinska M; Shcharbin D; Gomez Ramirez R; de la Mata FJ; Bryszewska M
    Future Med Chem; 2019 Jul; 11(14):1741-1756. PubMed ID: 31287722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes.
    Maroto-Díaz M; Elie BT; Gómez-Sal P; Pérez-Serrano J; Gómez R; Contel M; Javier de la Mata F
    Dalton Trans; 2016 Apr; 45(16):7049-66. PubMed ID: 26990859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbosilane metallodendrimers based on copper (II) complexes: Synthesis, EPR characterization and anticancer activity.
    Sanz Del Olmo N; Maroto-Díaz M; Gómez R; Ortega P; Cangiotti M; Ottaviani MF; de la Mata FJ
    J Inorg Biochem; 2017 Dec; 177():211-218. PubMed ID: 29031179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel "ruthenium cyclopentadienyl"-peptide conjugate complexes against human FGFR(+) breast cancer.
    Franco Machado J; Machuqueiro M; Marques F; Robalo MP; Piedade MFM; Garcia MH; Correia JDG; Morais TS
    Dalton Trans; 2020 May; 49(18):5974-5987. PubMed ID: 32314752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulating the anticancer properties of organometallic dendrimers using pyridylferrocene entities: synthesis, cytotoxicity and DNA binding studies.
    Govender P; Riedel T; Dyson PJ; Smith GS
    Dalton Trans; 2016 Jun; 45(23):9529-39. PubMed ID: 27193373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drug.
    Michlewska S; Kubczak M; Maroto-Díaz M; Sanz Del Olmo N; Ortega P; Shcharbin D; Gomez Ramirez R; Javier de la Mata F; Ionov M; Bryszewska M
    Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31450702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organometallic dendrimers based on Ruthenium(II) N-heterocyclic carbenes and their implication as delivery systems of anticancer small interfering RNA.
    Rodríguez-Prieto T; Michlewska S; Hołota M; Ionov M; de la Mata FJ; Cano J; Bryszewska M; Gómez R
    J Inorg Biochem; 2021 Oct; 223():111540. PubMed ID: 34273717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer activity of structurally related ruthenium(II) cyclopentadienyl complexes.
    Côrte-Real L; Mendes F; Coimbra J; Morais TS; Tomaz AI; Valente A; Garcia MH; Santos I; Bicho M; Marques F
    J Biol Inorg Chem; 2014 Aug; 19(6):853-67. PubMed ID: 24562604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis.
    Ang WH; Daldini E; Scolaro C; Scopelliti R; Juillerat-Jeannerat L; Dyson PJ
    Inorg Chem; 2006 Oct; 45(22):9006-13. PubMed ID: 17054361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New half-sandwich ruthenium(ii) complexes as proteosynthesis inhibitors in cancer cells.
    Ballester FJ; Ortega E; Porto V; Kostrhunova H; Davila-Ferreira N; Bautista D; Brabec V; Domínguez F; Santana MD; Ruiz J
    Chem Commun (Camb); 2019 Jan; 55(8):1140-1143. PubMed ID: 30631876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(alkylidenimine) Dendrimers Functionalized with the Organometallic Moiety [Ru(η⁵-C₅H₅)(PPh₃)₂]⁺ as Promising Drugs Against
    Gouveia M; Figueira J; Jardim MG; Castro R; Tomás H; Rissanen K; Rodrigues J
    Molecules; 2018 Jun; 23(6):. PubMed ID: 29914219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.
    Golbaghi G; Pitard I; Lucas M; Haghdoost MM; de Los Santos YL; Doucet N; Patten SA; Sanderson JT; Castonguay A
    Eur J Med Chem; 2020 Feb; 188():112030. PubMed ID: 31945643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of Ru-arene Complexes for Antitumor Drugs.
    Su W; Li Y; Li P
    Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of cytotoxicity by combining pyrenyl-dendrimers and arene ruthenium metallacages.
    Pitto-Barry A; Zava O; Dyson PJ; Deschenaux R; Therrien B
    Inorg Chem; 2012 Jul; 51(13):7119-24. PubMed ID: 22716166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumour and Toxicity Evaluation of a Ru(II)-Cyclopentadienyl Complex in a Prostate Cancer Model by Imaging Tools.
    Gano L; Pinheiro T; Matos AP; Tortosa F; Jorge TF; Gonçalves MS; Martins M; Morais TS; Valente A; Tomaz AI; Garcia MH; Marques F
    Anticancer Agents Med Chem; 2019; 19(10):1262-1275. PubMed ID: 30887931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel tetranuclear ruthenium(II) arene complexes showing potent cytotoxic and antimetastatic activity as well as low toxicity in vivo.
    Mohamed Subarkhan MK; Ren L; Xie B; Chen C; Wang Y; Wang H
    Eur J Med Chem; 2019 Oct; 179():246-256. PubMed ID: 31255925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling.
    Rahman FU; Bhatti MZ; Ali A; Duong HQ; Zhang Y; Ji X; Lin Y; Wang H; Li ZT; Zhang DW
    Eur J Med Chem; 2018 Sep; 157():1480-1490. PubMed ID: 30282320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elaborated study of Cu(II) carbosilane metallodendrimers bearing substituted iminopyridine moieties as antitumor agents.
    Carloni R; Sanz Del Olmo N; Canonico B; Montanari M; Ciacci C; Ambrosi G; de la Mata FJ; Ottaviani MF; García-Gallego S
    Eur J Med Chem; 2021 Apr; 215():113292. PubMed ID: 33631696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.